AKT1 and nonpapillary renal cell carcinoma: While mutations of the PI3K/AKT pathway were frequent both across (14.6%) as well as within each RCC subtype (16.2% of ccRCC, 9.8% of PRCC, and 18.9% of ChRCC), they correlated with decreased survival only in ChRCC (p = 0.0018) (Figures S2D and S2E and Table S2).